Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes

scientific article published on 01 June 2020

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00277-020-04094-3
P932PMC publication ID8772341
P698PubMed publication ID32488603

P50authorNeil E KayQ54295335
Kari G RabeQ56885267
Tait D ShanafeltQ89771809
William J ArchibaldQ90038362
Susan L SlagerQ92530010
Timothy G. CallQ110903651
Susan M. SchwagerQ110920181
P2093author name stringWei Ding
Yucai Wang
Joerg Herrmann
Jose F Leis
Asher A Chanan-Khan
Brian F Kabat
Sameer A Parikh
Eli Muchtar
Amie L Fonder
Saad S Kenderian
Amber B Koehler
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectatrial fibrillationQ815819
chronic lymphocytic leukemiaQ1088156
ibrutinibQ5984881
P304page(s)143-155
P577publication date2020-06-01
P1433published inAnnals of HematologyQ15766509
P1476titleAtrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes
P478volume100

Search more.